PDCD1 and neoplasm: Work from Delgoffe demonstrates how the state of the tumor (e.g., oxidative metabolism) can influence T cell responses to checkpoint blockade therapy and provide a predictive indicator to anti-PD-1 therapy responsiveness (241).